Patents by Inventor Emile Bellott

Emile Bellott has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Derivatives of 4-(thio- or selenoxanthene-9-ylidene)-piperidine or acridine and its use as a selective 5-HTreceptor antagonist
    Patent number: 7511064
    Abstract: The present invention relates to derivatives of 4-(Thio- or Selenoxanthene-9-ylidene)-piperidine or acridine and pharmaceutically acceptable salts thereof, use of these compounds as a medicament and for the manufacture of a medicament for treatment of a disease state which can be alleviated by treatment with a 5-HT2B antagonist.
    Type: Grant
    Filed: April 19, 2006
    Date of Patent: March 31, 2009
    Assignee: Biofrontera Bioscience GmbH
    Inventors: Hermann Lubbert, Christoph Ullmer, Emile Bellott, Mark Froimowitz, Douglas Gordon
  • SMMR (small molecule metabolite reporters) for use as in vivo glucose biosensors
    Publication number: 20070110672
    Abstract: Small Molecule Metabolite Reporters (SMMRs) for use as in vivo glucose biosensors, sensor compositions, and methods of use, are described. The SMMRs include boronic acid-containing xanthene, coumarin, carbostyril and phenalene-based small molecules which are used for monitoring glucose in vivo, advantageously on the skin.
    Type: Application
    Filed: June 26, 2006
    Publication date: May 17, 2007
    Inventors: Emile Bellott, Dongsheng Bu, James Childs, Christopher Lambert, Hubert Nienaber, Shirley Shi, Zhaolin Wang, Jerome Workman, Alex Zelenchuk
  • DERIVATIVES OF 4-(THIO-OR SELENOXANTHENE-9-YLIDENE)-PIPERIDINE OR ACRIDINE AND ITS USE AS A SELECTIVE 5-HT2B RECEPTOR ANTAGONIST
    Publication number: 20060183905
    Abstract: The present invention relates to derivatives of 4-(Thio- or Selenoxanthene-9-ylidene)-piperidine or acridine and pharmaceutically acceptable salts thereof, use of these compounds as a medicament and for the manufacture of a medicament for treatment of a disease state which can be alleviated by treatment with a 5-HT2B antagonist.
    Type: Application
    Filed: April 19, 2006
    Publication date: August 17, 2006
    Applicant: BIOFRONTERA BIOSCIENCE GmbH
    Inventors: Hermann Lubbert, Christoph Ullmer, Emile Bellott, Mark Froimowitz, Douglas Gordon
  • Derivatives of 4-(thio- or selenoxanthene-9-ylidene)-piperidine or acridine and its use as a selective 5-HTreceptor antagonist
    Patent number: 7060711
    Abstract: The present invention relates to derivatives of 4-(Thio- or Selenoxanthene-9-ylidene)-piperidine or acridine and pharmaceutically acceptable salts thereof, use of these compounds as a medicament and for the manufacture of a medicament for treatment of a disease state which can be alleviated by treatment with a 5-HT2B antagonist.
    Type: Grant
    Filed: October 25, 2002
    Date of Patent: June 13, 2006
    Assignee: Biofrontera Bioscience GmbH
    Inventors: Hermann Lubbert, Christoph Ullmer, Emile Bellott, Mark Froimowitz, Douglas Gordon
  • Derivatives of 4-(Thio- or Selenoxanthene-9-ylidene)-piperidine or acridine and its use as a selective 5-HT2B receptor antagonist
    Publication number: 20030166672
    Abstract: The present invention relates to derivatives of 4-(Thio- or Selenoxanthene-9-ylidene)-piperidine or acridine and pharmaceutically acceptable salts thereof, use of these compounds as a medicament and for the manufacture of a medicament for treatment of a disease state which can be alleviated by treatment with a 5-HT2B antagonist.
    Type: Application
    Filed: October 25, 2002
    Publication date: September 4, 2003
    Inventors: Hermann Lubbert, Christoph Ullmer, Emile Bellott, Mark Froimowitz, Douglas Gordon
  • 1-Methyl-4- (3-ethoxy-9H-thioxanthene-9-ylidene) -piperidine and its use as 5-HT2B/H1 receptor antagonist
    Publication number: 20030022920
    Abstract: The present invention relates to 1-methyl-4-(3-ethoxy-9H-thioxanthene-9-ylidene)-piperidine and pharmaceutically acceptable salts thereof, use of 1-methyl-4-(3-ethoxy-9H-thioxanthene-9-ylidene)-piperidine as a medicament and for the manufacture of a medicament for treatment of a disease state which is alleviable by treatment with a 5-HT2B or H1 o or 5-HT2B/H1 receptor antagonists.
    Type: Application
    Filed: May 24, 2002
    Publication date: January 30, 2003
    Inventors: Christoph Ullmer, Hermann Lubbert, Mark Froimowitz, Emile Bellott, Douglas Gordon